📊 MGTX Key Takeaways
Is MeiraGTx Holdings plc (MGTX) a Good Investment?
MeiraGTx is a pre-commercial biopharmaceutical company with severe financial distress characterized by negative stockholders' equity of -$5.8M, indicating liabilities exceed assets. Despite 144.6% revenue growth, the company is burning cash at an alarming rate with -$50.2M free cash flow and operating losses of -$106.0M, with only 16.9 months of cash runway at current burn rate.
MeiraGTx shows headline revenue growth, but the underlying fundamentals remain very weak: operating losses are larger than revenue, net margins are deeply negative, and free cash flow remains substantially negative. The balance sheet is stressed with negative stockholders' equity and sub-1.0 liquidity ratios, which raises meaningful financing and going-concern risk unless the company can materially improve cash generation or secure additional capital on reasonable terms.
Why Buy MeiraGTx Holdings plc Stock? MGTX Key Strengths
- Strong revenue growth of 144.6% YoY indicating market traction for pipeline programs
- Adequate cash position of $65.9M provides near-term liquidity runway
- Increased insider activity with 17 Form 4 filings suggesting management confidence in development progress
- Revenue grew 144.6% year over year, indicating meaningful top-line progress
- Cash balance of $65.93M provides some near-term operating flexibility
- EPS improved 33.0% year over year, suggesting losses per share narrowed versus the prior period
MGTX Stock Risks: MeiraGTx Holdings plc Investment Risks
- Negative stockholders' equity of -$5.8M indicates technical insolvency and existential bankruptcy risk
- Severe cash burn of -$50.2M annually with negative operating cash flow of -$46.4M, requiring capital raise or profitability
- Profoundly negative margins (operating margin -130.2%, net margin -140.3%) with no clear path to profitability in near term
- Current ratio of 0.75x indicates liquidity stress and inability to cover short-term obligations without asset sales
- Pre-commercial stage with revenue growth but no clear regulatory approval timeline for monetization
- Operating margin of -130.2% and net margin of -140.3% show the business is far from sustainable profitability
- Negative stockholders' equity and a current ratio of 0.75x indicate balance-sheet and liquidity stress
- Operating cash flow of -$46.36M and free cash flow of -$50.19M imply ongoing external funding dependence
Key Metrics to Watch
- Cash position and runway duration until next financing required
- Operating cash flow improvement trajectory and path to cash flow breakeven
- Clinical trial progress and regulatory milestone achievements for lead programs
- Revenue sustainability and ability to achieve profitability without additional capital dilution
- Quarterly operating cash burn and ending cash balance
- Whether revenue growth converts into materially lower operating losses and improved liquidity
MeiraGTx Holdings plc (MGTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
MGTX Profit Margin, ROE & Profitability Analysis
MGTX vs Healthcare Sector: How MeiraGTx Holdings plc Compares
How MeiraGTx Holdings plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MeiraGTx Holdings plc Stock Overvalued? MGTX Valuation Analysis 2026
Based on fundamental analysis, MeiraGTx Holdings plc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MeiraGTx Holdings plc Balance Sheet: MGTX Debt, Cash & Liquidity
MGTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: MeiraGTx Holdings plc's revenue has grown significantly by 184% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.12 indicates the company is currently unprofitable.
MGTX Revenue Growth, EPS Growth & YoY Performance
MGTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $410.0K | -$20.4M | $-0.55 |
| Q2 2025 | $282.0K | -$20.4M | $-0.48 |
| Q3 2024 | $5.1M | -$20.4M | $-0.55 |
| Q2 2024 | $282.0K | -$20.4M | $-0.53 |
| Q1 2024 | $697.0K | -$20.4M | $-0.32 |
| Q3 2023 | $4.8M | -$29.6M | $-0.74 |
| Q2 2023 | $3.5M | -$29.6M | $-0.53 |
| Q1 2023 | $3.3M | -$30.4M | $-0.62 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MeiraGTx Holdings plc Dividends, Buybacks & Capital Allocation
MGTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for MeiraGTx Holdings plc (CIK: 0001735438)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MGTX
What is the AI rating for MGTX?
MeiraGTx Holdings plc (MGTX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MGTX's key strengths?
Claude: Strong revenue growth of 144.6% YoY indicating market traction for pipeline programs. Adequate cash position of $65.9M provides near-term liquidity runway. ChatGPT: Revenue grew 144.6% year over year, indicating meaningful top-line progress. Cash balance of $65.93M provides some near-term operating flexibility.
What are the risks of investing in MGTX?
Claude: Negative stockholders' equity of -$5.8M indicates technical insolvency and existential bankruptcy risk. Severe cash burn of -$50.2M annually with negative operating cash flow of -$46.4M, requiring capital raise or profitability. ChatGPT: Operating margin of -130.2% and net margin of -140.3% show the business is far from sustainable profitability. Negative stockholders' equity and a current ratio of 0.75x indicate balance-sheet and liquidity stress.
What is MGTX's revenue and growth?
MeiraGTx Holdings plc reported revenue of $81.4M.
Does MGTX pay dividends?
MeiraGTx Holdings plc does not currently pay dividends.
Where can I find MGTX SEC filings?
Official SEC filings for MeiraGTx Holdings plc (CIK: 0001735438) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MGTX's EPS?
MeiraGTx Holdings plc has a diluted EPS of $-1.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MGTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, MeiraGTx Holdings plc has a STRONG SELL rating with 91% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MGTX stock overvalued or undervalued?
Valuation metrics for MGTX: ROE of N/A (sector avg: 15%), net margin of -140.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MGTX stock in 2026?
Our dual AI analysis gives MeiraGTx Holdings plc a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MGTX's free cash flow?
MeiraGTx Holdings plc's operating cash flow is $-46.4M, with capital expenditures of $3.8M. FCF margin is -61.7%.
How does MGTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -140.3% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.75 (avg: 2).